Developmental Studies Hybridoma Bank

The Developmental Studies Hybridoma Bank (DSHB) is a National Resource established by the National Institutes of Health (NIH) in 1986 to bank and distribute at cost hybridomas and the monoclonal antibodies (mAbs) they produce to the basic science community worldwide. It is housed in the Department of Biology at the University of Iowa.

Developmental Studies Hybridoma Bank (DSHB)
Founded1986
TypeSelf-funded organization
Location
ServicesBank and distribute hybridomas and cell products

Mission

The mission of the DSHB is four-fold:

  • Keep product prices low to facilitate research (currently 40.00 USD per ml of supernatant).
  • Serve as a repository to relieve scientists of the time and expense of distributing hybridomas and the mAbs they produce.
  • Assure the scientific community that mAbs with limited demand remain available.
  • Maintain the highest product quality, provide prompt customer service and technical assistance.

Description

The DSHB is directed by David R. Soll at the University of Iowa. There are currently over 5000 hybridomas in the DSHB collection.[1] The DSHB has obtained hybridomas from a variety of individuals and institutions, the latter including the Muscular Dystrophy Association, the National Cancer Institute, the NIH Common Fund, and the European Molecular Biology Laboratory (EMBL). The DSHB eagerly awaits new contributions. First time customers must agree to the DSHB terms of usage that products will be used for research purposes only, and that they cannot be commercialized or distributed to a third party. Researchers also agree to acknowledge both the DSHB and the contributing investigator and institution in publications that benefit from the use of DSHB products and provide to the DSHB citations of all publications. Individuals or institutions can deposit hybridomas for distribution at no cost. Contributing to the DSHB does not preclude the depositor from licensing cell lines for commercial purposes. The DSHB does not own any contributed intellectual property. The intellectual property remains that of the scientist and/or institution that banks the hybridomas. The DSHB covers the operating costs of maintaining, improving, producing and distributing products in the collection.

History

The DSHB was created in 1986 by the NIH to bank and distribute hybridomas and the monoclonal antibodies (mAbs) they produce to the general scientific community in order to facilitate research. The DSHB was moved from Johns Hopkins University to the University of Iowa in 1996, and placed under the directorship of David R. Soll. The DSHB has been self-funded since 1997 and relies on no outside funding.

  • Cardiac Muscle
  • CD Markers
  • Cell Adhesion
  • Cell Biomarkers
  • Cytoskeleton
  • Disease Biomarkers
  • EMBL Protein Binders (Affinomics)
  • Enzymes
  • Epitope Tags
  • Extracellular Matrix
  • Microbes (Bacteria, Fungi, Viruses)
  • Neurodevelopment
  • Muscular Dystrophy Association mAbs
  • NIH Common Fund Protein Capture Reagents
  • NIH NCI CPTAC Cancer Targets
  • Receptors
  • Organelle-specific Biomarkers
  • RNA/DNA Regulation
  • Secreted Proteins
  • Epitope Tags
  • Skeletal Muscle
  • Transcription Factors

Noteworthy Depositors

Nobel Prize and Alfred P. Sloan, Jr. Prize winner J. Michael Bishop deposited the anti c-MYC hybridoma 9e 10

Nobel Prize winner Sir John Gurdon deposited MyoD clone D7F2

Nobel Prize winner Eric F. Wieschaus deposited 7 hybridomas

National Academy of Sciences Members who have deposited hybridomas


References
  1. "Products".
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.